Top > Search of International Patents > DOUBLE-STRANDED NUCLEIC ACID MOLECULE, DNA, VECTOR, CANCER CELL GROWTH INHIBITOR, CANCER CELL MIGRATION INHIBITOR, AND DRUG

DOUBLE-STRANDED NUCLEIC ACID MOLECULE, DNA, VECTOR, CANCER CELL GROWTH INHIBITOR, CANCER CELL MIGRATION INHIBITOR, AND DRUG

Foreign code F160008775
File No. S2016-0061-N0
Posted date Jul 25, 2016
Country WIPO
International application number 2015JP067054
International publication number WO 2015190606
Date of international filing Jun 12, 2015
Date of international publication Dec 17, 2015
Priority data
  • P2014-122067 (Jun 13, 2014) JP
Title DOUBLE-STRANDED NUCLEIC ACID MOLECULE, DNA, VECTOR, CANCER CELL GROWTH INHIBITOR, CANCER CELL MIGRATION INHIBITOR, AND DRUG
Abstract Provided is a double-stranded nucleic acid molecule for inhibiting the expression of non-coding RNA that includes base sequences represented by SEQ ID NOs: 1 to 4 or a portion of said base sequences, wherein the double-stranded nucleic acid molecule contains: (a) a sense strand that includes nucleotide sequences corresponding to target sequences represented by SEQ ID Nos. 5 to 11 or 26 to 31; and (b) an antisense strand that is complementary to the sense strand in (a) and forms a double strand with the sense strand.
Scope of claims [claim1]
1.  A plasmoid complex nuclear fusion reactor, the muon - - muon in order to obtain a nuclear fusion reaction plasmoid complex nuclear fusion reactor,  And the target container for ca1.  A double-stranded nucleic acid molecules for inhibiting the expression of non-coding RNA,  The double-stranded nucleic acid molecules, (A) SEQ ID NO: a sense strand containing from 5 to 11 and a nucleotide sequence corresponding to the target sequence represented by any one of 26-31, (B) comprises an antisense strand comprising a nucleotide sequence complementary to said sense strand to form the sense strand and double strand of said (a),  The non-coding RNA is, SEQ ID NO: double-stranded nucleic acid molecule which comprises at least one of the nucleotide sequences and portions thereof represented by 1-4.
[2]
[claim2]
2.  Sense strand, SEQ ID NO: 5,6,9,10,27,28,29,30, and claim 1 is the sense strand comprising a nucleotide sequence corresponding to the target sequence represented by any one of 31 double-stranded nucleic acid molecule.
[3]
[claim3]
3.  Sense strand, SEQ ID NO: 6, and double-stranded nucleic acid molecule according to any one of claims 1 to 2 is the sense strand comprising a nucleotide sequence corresponding to the target sequence represented by any one of 28.
[4]
[claim4]
4.  Double-stranded nucleic acid molecule according to any of claims 1 3 is either double-stranded RNA and double-stranded RNA-DNA chimera.
[claim5]
5.

Double-stranded nucleic acid molecule according to any of claims 1 4 is either siRNA and chimera siRNA.
[6]
[claim6]
6.  DNA which comprises a nucleotide sequence encoding a double-stranded nucleic acid molecule according to any one of claims 1 to 5.
[7]
[claim7]
7.  Vector comprising the DNA of claim 6.
[8]
[claim8]
8.  Double-stranded nucleic acid molecule according to any of claims 1 5, cancer cell proliferation suppressing agent which comprises at least one of the vectors described DNA, and claim 7 according to claim 6.
[9]
[claim9]
9.  Double-stranded nucleic acid molecule according to any one of claims 1 to 5, cancer cell migration inhibiting agent characterized in that it comprises at least one of the vectors described DNA, and claim 7 according to claim 6.
[10]
[claim10]
10.  A pharmaceutical for preventing or treating cancer, pharmaceutical, which comprises claims cancer cell growth inhibitor according to Item 8, and at least one cancer cell migration inhibitor according to claim 9.using a nuclear fusion reaction,  Is connected to the target container, and the solid hydrogen ice fog source for forming the incident solid hydrogen in the target container solid hydrogen ice fog,  Is connected to the target vessel, the magnetization plasmoid in the solid hydrogen ice fog in the target container as well as generate a magnetized plasmoid to transport, solid - and the plasmoid generation source for forming a plasma complex area,  And plasma muon source in order to obtain the incident nuclear reaction the muon in the composite area, - which is connected to the target container, solid  Muon characterized in that it comprises a - plasmoid complex fusion reactor.
[2]
[claim11]
2.  Muon according to claim 1 - in the plasmoid complex fusion reactor, the solid hydrogen ice fog sources and plasmoid generation sources, solid is generated - control as plasma complex area is maintained long time compared to the lifetime of the muon plasmoid complex fusion reactor - muons, characterized in that it is.
[3]
[claim12]
3.  Muon according to claim 1 or claim 2 - in the plasmoid complex fusion reactor, the plasmoid generating source, the magnetization plasmoid faster than the time scale of the plasma diffusion or relaxation, to transport in a solid hydrogen ice fog in the target container muon, characterized in that - plasmoid complex fusion reactor.
[4]
[claim13]
4.  Muon according to any one of claims 1 to 3 - the plasmoid complex fusion reactor, the muon generating source, muons characterized by incident muons while solid hydrogen ice fog is sublimated - plasmoid compound nucleus fusion reactor.
[5]
[claim14]
5.  Muon according to any one of claims 1 to 4 - A plasmoid composite nuclear fusion reactor, further connected to the target vessel, by including an energy transducer for recovering the fusion product plasmoid complex fusion reactor - muon characterized.
[6]
[claim15]
6.  Muons of claim 5 - In plasmoid complex fusion reactor, the plasmoid source is characterized by inducing the fusion product energy converter using a magnetic field to confine the generated magnetization plasmoid as a guide magnetic field muon - plasmoid complex fusion reactor.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • SAITAMA MEDICAL UNIVERSITY
  • Inventor
  • INOUE SATOSHI
  • IKEDA KAZUHIRO
  • INOUE KUNIKO
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close